The Supervisory Board is comprised of independent, non-executive individuals who are charged with supervising and advising Crucell's Management Board.

The members of the Supervisory Board are:

Jan Pieter Oosterveld [1944] - Chairman

Jan Pieter Oosterveld has served as Chairman of our Supervisory Board since June 2, 2006. He was nominated as a Supervisory Board member in May 2004, and was officially appointed at our AGM on June 3, 2004. He retired from Royal Philips Electronics N.V. on April 1, 2004, after an international career of 32 years. He was responsible for corporate strategy, corporate alliances and the joint ventures with LGE on CRT and LCD. In the latter responsibility he was the Chairman of the Board of LG.Philips Ltd, which went public in April 2004, and Vice Chairman of the Board of LG.Philips Displays B.V. He was also CEO of Philips Asia Pacific. He has a degree in Mechanical Engineering from the Technical University Eindhoven, the Netherlands, and holds an MBA from the Instituto de Estudios Superiores de la Empresa (IESE) in Barcelona, Spain. He was appointed Professor at IESE in 2003. Mr Oosterveld is a member of the boards of Barco (Kortrijk, Belgium), Atos Origin (Paris, France), Cookson Electronics Group (London, UK) and Continental (Hannover, Germany).

• Expiry of Term — 2014

Arnold Hoevenaars [1949]

Arnold Hoevenaars has been attending our Supervisory Board meetings as an observer since July 2004, and was officially appointed to the board at our AGM on June 2, 2005. Mr Hoevenaars is a chartered accountant in the Netherlands, and his previous positions include, among others, Chairman of the Management Board of the Achmea Group, Chairman of the Board of Directors and Chairman/CEO of the Executive Board of Eureko B.V. and member of the Management Board and Chief Financial Officer of Royal Boskalis Westminster N.V.

• Expiry of Term — 2013

Stephen Brown (Steve) Davis [1957]

Steve Davis was appointed as a member of our Supervisory Board during the 2008 AGM. Mr Davis was CEO of Corbis until 2007 and now acts as a senior advisor to the company. He has held positions within the United Nations High Commissioner for Refugees and several refugee resettlement programs. Currently he is a member of the Board of Trustees for PATH, a non-profit organization focused on improving public health in the developing world. He is a member of the Board of Trustees for the Fred Hutchinson Cancer Research Center. He holds a board position in Intrepid Learning Solutions, Seattle Foundation, and PlanetOut Inc. Mr. Davis holds a Bachelor of Arts from Princeton University, a Master of Arts from the University of Washington and a Doctorate in Law from Columbia University School of Law.

• Expiry of Term — 2012

Phillip M. Satow [1941]

Phillip M. Satow has been a member of Crucell’s Supervisory Board since its incorporation in 2000. He spent 14 years at Pfizer, Inc. (PFE-NYSE) where his last position was Vice President, Pharmaceutical Development, Pfizer Europe. From 1985 to 1997, he was Executive Vice President Marketing at Forest Laboratories, Inc. From 1998 to 1999 he was President of Forest Pharmaceuticals, Executive Vice President of Forest Laboratories Inc. and a member of its board of directors. Mr Satow currently serves on the boards of Forest Laboratories Inc. (FRX) and Eyetech Pharmaceuticals Inc. (EYET), and is Chairman and CEO of JDS Pharmaceuticals LLC, a privately held pharmaceutical company. Mr Satow received a Masters in Economics from Georgetown University.

• Expiry of Term — 2013

Claes E. Wilhelmsson [1939]

Dr Wilhelmsson has served as a member of Crucell’s Supervisory Board since May 2003. He was previously the Executive Director of research and development at AstraZeneca PLC, with responsibility for AstraZeneca's global R&D, from 1999 until July 2002. Dr Wilhelmsson joined Astra in 1985 and held various positions until the company merged with Zeneca in 1999. Before joining Astra he was a lecturer and researcher at the University of Göteborg in Sweden, where he also completed his medical education and PhD. He currently serves on the boards of a number of biotechnology and start-up companies. Dr Wilhelmsson previously served on the board of AstraZeneca PLC.

• Expiry of Term — 2011

Floris Waller [1958]

Floris Waller was appointed as a member of our Supervisory Board on June 5, 2009. He was CFO and board member at Corporate Express N.V. (previously Buhrmann) from 1999 until 2008. Mr Waller was a member of the Supervisory Board and Audit Committee of Univar N.V. from 2005 until 2007. From 1984 to 1999, he held various senior finance and operational positions at Unilever N.V./Plc. Currently he is CFO and board member of Pon Holdings B.V. and is a member of the Supervisory Board of Klaverblad, a local insurance company in the Netherlands. Mr Waller holds a Master of Science degree in Business Economics from Erasmus Universiteit of Rotterdam and is a chartered accountant. Mr Waller is a Dutch citizen.

• Expiry of Term — 2013

George Siber [1944]

George Siber was appointed to Crucell’s Supervisory Board during the 2010 AGM. He is a leading global authority in vaccine research and development, where he has around 35 years of post-academic experience. As Executive Vice President and Chief Scientific Officer of Wyeth Vaccines, he oversaw the development and launch of at least six products over a 10-year period. Before that, he was Director of the Massachusetts Public Health Biologic Laboratories and Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. Currently, Dr Siber is a scientific advisor to the PATH Pneumococcal Vaccine Project, Malaria Vaccine Initiative, Gates Maternal Immunization Program, Stop TB Task Force and several vaccine companies. He was appointed to the US National Advisory Allergy and Infectious Diseases Council in 2010. He is Executive Chairman of Genocea Biosciences and Non-executive Director of Selecta Biosciences, Inc., both in Boston. Dr Siber holds a medical degree from McGill University in Canada, and specialized in internal medicine and infectious diseases at Rush Medical Center in Chicago and Beth Israel and Children's Hospital at Harvard Medical School in Boston, USA.

• Expiry of Term — 2014

James Shannon [1956]

James Shannon has over 20 years of experience in senior positions involving pharmaceutical development and registration, most recently as Head of Global Development at Novartis Pharma AG in Switzerland. Mr Shannon was Head of Regulatory Affairs at Sandoz in Basel when that company merged with Ciba-Geigy to form Novartis in 1996, and he headed the office responsible for integrating the two R&D organizations in the wake of the merger. He subsequently led the launch of Diovan (valsartan), which became Novartis’ lead product, and filled a number of other senior development positions, culminating in his appointment as Head of Global Development in 2005. Mr Shannon retired from Novartis in 2008. He holds graduate and postgraduate degrees in medicine and cardiology from Queens University in Belfast, Ireland, and worked as a clinician for around seven years before joining the industry. He is currently President and CEO of Cerimon Pharmaceuticals, Inc. and serves on the Boards of Arch Therapeutics, Endocyte Inc, Mannkind Corporation and Xanodyne Pharmaceuticals, Inc.

• Expiry of Term — 2014

William (Bill) M.Burns [1947]

Bill Burns, a British national, has built a distinguished track record in the pharmaceutical industry over the past 40 years. His most recent position was as CEO of the Pharmaceuticals Division of Roche, which he headed for 8 years to December 2009. Mr Burns joined Roche in 1986, was promoted to Head of Global Business Development and Strategic Marketing in 1991, and was appointed to Roche’s Corporate Executive Committee in 2000. Before joining Roche, Mr Burns worked at Beecham Pharmaceuticals for 17 years, starting as a management trainee in 1969 and taking on progressively senior positions in the UK and Japan. He holds a BA (Honours degree) in Business Economics from Strathclyde University, Scotland. Mr Burns has represented Roche on the board of the European and international pharmaceutical industry associations EFPIA and IFPMA, and was Chairman of Interpharma, the Swiss research companies’ trade association. He has served on the board of Genentech and is currently a board member for Roche Holding AG and Chugai Pharmaceutical Co., Ltd.

• Expiry of Term — 2014